Can You Take Saxenda and Wegovy Together?

Step 1: Understand what Saxenda and Wegovy actually do, and why that rules out combining them

Saxenda contains liraglutide, injected once daily. Wegovy contains semaglutide, injected once weekly. Both are GLP-1 receptor agonists, which means they work by binding to and activating the same receptor (the glucagon-like peptide-1 receptor) that sits in your gut, brain and pancreas. This receptor slows gastric emptying, reduces appetite signals and influences insulin release.

Because they act on exactly the same receptor via the same mechanism, using both at once doesn't create a synergistic effect. It creates an additive burden on a single pathway, with no additional therapeutic ceiling to aim for. Your GLP-1 receptors are already occupied by one agent. The second has nowhere useful to go, and its dose-dependent side effects still arrive in full.

The NHS medicines guidance on semaglutide and the Wegovy SmPC both state clearly that patients should not use semaglutide alongside other GLP-1 receptor agonists. The same instruction appears in Saxenda's prescribing information. This isn't a precautionary hedging, it's a hard contraindication, and no licensed prescriber in the UK would advise combining them. If you've seen this suggestion online, it hasn't come from a regulated clinical source.

Our guide to semaglutide explains in more detail how the GLP-1 pathway works and what semaglutide does at a pharmacological level, which is useful background if you want to understand the mechanism before a consultation.

Step 2: Recognise the specific harms this combination would cause

The risks here are not theoretical. GLP-1 medicines already carry a well-documented gastrointestinal side-effect profile, nausea, vomiting, diarrhoea and constipation are common, particularly when starting or increasing a dose. Layering a second GLP-1 agent on top dramatically amplifies that profile, without any counter-balancing benefit.

Severe vomiting and diarrhoea can cause rapid dehydration, which puts strain on the kidneys. Persistent dehydration with reduced oral intake (which GLP-1 medicines already encourage by suppressing appetite) is a recognised route to acute kidney injury. Pancreatitis is a rarer but serious concern with GLP-1 medicines individually; the MHRA issued a Drug Safety Update in January 2026 specifically flagging acute pancreatitis as a known risk with this medicine class, with the instruction to seek urgent help for severe stomach pain that radiates to the back. Combining two agents would heighten this risk further.

There is also the matter of blood sugar. For people without diabetes, significant hypoglycaemia on GLP-1 monotherapy is uncommon, but stacking two agents creates unpredictability that a prescriber cannot safely monitor or anticipate. The MHRA's Yellow Card scheme exists partly to surface exactly this kind of harm when it occurs outside trial conditions. If you've experienced an adverse effect from any medicine, it can be reported there.

It's worth reading the fuller Wegovy guide for context on side effects and how they're typically managed within a single-medicine treatment plan, because good aftercare makes a significant difference to tolerability.

Step 3: Know what is licensed for weight management in the UK, and how switching works

Saxenda (liraglutide) and Wegovy (semaglutide injection) are both licensed for weight management in the UK for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. They are alternatives within the same medicine class, not medicines designed to be used in sequence within the same week or month without a proper gap.

A third option entered the UK market in 2025: Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist, the only medicine licensed for weight management in the UK that works on two pathways rather than one. NICE recommended it for NHS use in December 2024 (TA1026). The NICE appraisal of tirzepatide sets out the eligibility criteria in full. In clinical trials, tirzepatide produced greater average weight loss than semaglutide 2.4mg, so if Wegovy at its full dose hasn't delivered the results you were hoping for, tirzepatide is a legitimate clinical alternative to discuss with a prescriber, not a second medicine to add on top.

If you're considering switching from Saxenda to Wegovy, or from either to tirzepatide, the question of timing matters. A prescriber will want to know your current dose, how long you've been on treatment, what results you've seen and what side effects you've had. Our comparison of Wegovy and Saxenda covers the key differences (mechanism, dosing schedule, evidence base and practical factors like injection frequency) to help you think through the options before that conversation. You might also find the guide on where to get Wegovy useful if you're thinking about private routes.

For anyone currently on Wegovy who wants to understand whether HRT or other concurrent medicines raise similar questions, this page on Wegovy and HRT addresses the interactions that matter most in practice. Questions about combining semaglutide with other treatments more broadly are covered in the semaglutide combinations guide. And if you've encountered claims about combining peptides with GLP-1 medicines, the MOTS-C and semaglutide page addresses that category of question directly.

If you'd like to explore whether switching or starting treatment is clinically suitable for you, our prescribers review consultations the same day. Take a look at the weight-loss treatment options at nume to see what's available, or read more about how we approach weight management before getting started. Speak to our prescribers, it's a free consultation, with no obligation.